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ABSTRACT
During development of a novel treatment for cancer patients, the tumor 
microenvironment and its interaction with the tumor cells must be considered. Aspects 
such as the extracellular matrix (ECM), the epithelial-mesenchymal transition (EMT), 
secreted factors, cancer-associated fibroblasts (CAFs), the host immune response, 
and tumor-associated microphages (TAM) are critical for cancer progression and 
metastasis. Additionally, signaling pathways such as the nuclear factor κB (NF-
κB), transforming growth factor β (TGFβ), and tumor necrosis factor α (TNFα) can 
promote further cytokine release in the tumor environment, and impact tumor 
progression greatly. Importantly, cytokine overexpression has been linked to drug 
resistance in cancers and is therefore an attractive target for combinational therapies. 
Specific inhibitors of cytokines involved in signaling between tumor cells and the 
microenvironment have not been studied in depth and have great potential for use 
in personalized medicines. Together, the interactions between the microenvironment 
and tumors are critical for tumor growth and promotion and should be taken into 
serious consideration for future novel therapeutic approaches.
INTRODUCTION
The cells surrounding a tumor make up a molecular 
microenvironment known as the stroma. The stroma can 
be influenced and can in turn influence the growth and 
formation of tumors and new metastases. Origination of 
this microenvironment can be linked to the “seed and soil” 
concept with the original cancer cells, termed “seeds,” and 
the microenvironment, termed “soil.” The cancer cells 
grow in new metastases just as “seeds” can grow in new 
areas of “soil” [1]. Like soil in nature, the components in 
the microenvironment are very complex. It includes the 
extracellular matrix (ECM), a variety of secreted factors, 
as well as different types of cells. 
ECM plays a critical role in the tumor 
microenvironment. In order to form a tumor, cancer cells 
must form attachments to the ECM and communicate 
with other cells, such as tumor-associated neutrophils, 
cancer-associated fibroblasts, and myeloid-derived 
suppressor cells. Then, the tumor cells can colonize the 
microenvironment and form a metastasis [2]. The ECM 
is especially important in tumor formation and invasion 
as cells respond and adapt to the local microenvironment 
to progress to malignancy. This involves both deregulated 
proliferation of tumor cells and modification of 
the immediate environment to favor cell survival, 
angiogenesis, and spread of the tumor. Evidence has 
shown that aberrant expression of factors that regulate 
the ECM can lead to increased tumor formation. For 
instance, decrease of secreted protein acidic and rich in 
cysteine (SPARC), a protein involved in regulation of 
morphogenesis and cellular differentiation, led to increase 
of tumor formation of implanted tumors [3]. Inhibition of 
chemokines such as growth-regulated α protein (GROα, 
also named CXCL1) can also increase cell proliferation 
in melanoma, leading to enhanced tumor growth [4]. 
Moreover, overexpression of cytokines such as tumor 
necrosis factor α (TNFα), a cytokine involved in several 
signaling pathways and in inflammation, could lead to 
increased tumor formation in nude mice [5]. Factors that 
can degrade the ECM also facilitate tumor formation 
and invasion. For instance, matrix metalloproteinases 
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(MMPs) have been implicated in degradation of basement 
membranes and ECM, facilitating tumor cell invasion and 
metastasis as well as promoting cell proliferation, survival, 
and angiogenesis [6]. 
Besides the ECM, another important aspect that 
can lead to cancer formation and invasion is a process 
termed epithelial-mesenchymal transition (EMT) of cancer 
cells. EMT can increase cancer cells’ migratory capacity, 
invasiveness, resistance to apoptosis, and the production 
of ECM components [7]. Many factors originating in the 
microenvironment can help to induce EMT, including 
epidermal growth factor (EGF), platelet-derived growth 
factor (PDGF), and transforming growth factor β (TGFβ). 
These factors may functionally activate EMT-inducing 
transcription factors, such as Snail (SNAI1), Slug 
(SNAI2), zinc finger E-box binding homeobox 1 (ZEB1), 
Twist family BHLH Transcription Factor 1 (Twist), 
Goosecoid (GSC), and forkhead box protein C2 (FOXC2) 
in cancer cells [8-13]. For example, TGFβ has been 
implicated in the repression of e-cadherin, leading to the 
increased invasiveness of tumor cells and the activation 
of Sma and Mad (SMAD) and mitogen-activated protein 
kinase (MAPK) signaling pathways, which all can 
contribute to the induction of EMT [14]. In addition to 
different cytokines and transcription factors, disruption 
of cell-cell adhesion molecules such as cadherins and 
the cell-ECM adhesions mediated by integrins can also 
contribute to EMT, resulting in tumor invasion [15, 16]. 
“Invasion” of cancer and “metastasis formation” 
involve the steps of intravasation (the invasion of cancer 
cells through the basal membrane into a blood or lymphatic 
vessel), extravasation (transport through the circulation), 
formation of micrometastases, and colonization [8, 15]. 
Both “Invasion” and “metastatic formation” require a 
specific microenvironment. “Invasion” is affected by the 
microenvironment in many ways. Activation of nearby 
cells in the stroma including fibroblasts, endothelial 
cells and macrophages can lead to reorganization of the 
ECM and release of growth factors, therefore promoting 
tumor growth [17-19]. On the other hand, even though 
“metastatic formation” is very heterogeneous and adaptive 
to diverse molecular and unhospitable microenvironments, 
it can still be facilitated by signaling of cells and other 
factors of the cancer microenvironment [20]. Macrophages 
in the microenvironment can promote invasion of cancer 
cells by producing EGF. Tumor-associated macrophages 
(TAMs) gather around blood vessels and create gradients 
of EGF within the tumor environment that attract tumor 
cells towards blood vessels and promote intravasation 
[21].
In addition to ECM, EMT, and the different factors 
described above, non-cancerous cells also comprise a 
major part of the tumor environment that can signal 
and be signaled by released chemokines and cytokines. 
For instance, the work of Luis Parada showed that mice 
with neurofibromatosis type 1 with only a loss of Nf1 
heterozygosity in Schwann cells were unable to form 
neurofibroma, but that Nf1 haploinsufficiency in a second 
type of cell - mast cells, was required for tumor formation. 
A separate cell-signaling ligand, stem cell growth factor 
(SGF), which binds to cKIT, a SCF receptor, was also 
needed for mast cell recruitment for tumor formation [22]. 
In short, the “soil” made up of the proteins, growth 
factors, and other non-tumor cells is a crucial part of 
tumor formation, invasion, and metastasis. It is important 
to consider and understand the interplay between the 
microenvironment and tumors when pursuing future 
therapeutics for cancers. Below, we will discuss some 
aspects of this microenvironment in details.
CYTOKINE SECRETION, 
INFLAMMATION, THE HOST IMMUNE 
RESPONSE AND TUMOR PROGRESSION 
A major part of the tumor microenvironment 
are different secreted factors, which play important 
roles in inflammation and cell growth. For many years, 
inflammation has been known to play a role in tumor 
formation. In 1991, Parsonnet et al. reported that after 
infecting cells with bacteria, they observed an increased 
development of cancer where there was inflammation 
[23]. They confirmed that constant cell proliferation in the 
stroma of a tumor was associated with an environment rich 
in inflammatory cells [23]. 
The relationship between inflammation and 
cancer is deeply intertwined. Inflammation is induced 
in tumor through neoplasia-associated angiogenesis and 
lymphangiogenesis. This creates an organization of blood 
vessels and lymphatics where neoplastic cells can interact 
with other mesenchymal, hematopoietic, lymphoid cells, 
and the ECM. Importantly, neoplastic cells themselves 
can produce arrays of cytokines and chemokines that 
are chemoattractants for other non-cancer cells, such 
as granulocytes, mast cells, monocytes/macrophages, 
fibroblasts and endothelial cells, all of which are needed 
for tumor formation. Besides cytokine release, proteolytic 
enzymes such as metalloproteases can also be secreted 
through activated fibroblasts and infiltrating inflammatory 
cells. Together these released factors can coordinate and 
act to recruit cells to the location of tumorigenesis by 
remodeling of the ECM. Ultimately, these factors promote 
tumor growth, stimulate angiogenesis, induce fibroblast 
migration and maturation, and enable metastatic spread 
through invasion into other systems. 
To date, ample evidence suggests that TAMs aid in 
inflammation-mediated infiltration of neoplastic tumors 
as well. TAMs can be activated by interleukin-2 (IL-
2) to go through apoptosis, but also can produce many 
angiogenic and lymphogenic growth factors which further 
mediate neoplastic progression [24]. Fusion of TAMs and 
normal cells has also been found as a way for the tumor 
cells and microenvironment to communicate in a cell-
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cell manner [25]. Chronic overexpression of mediators 
of inflammation, such as TNFα and TGFβ produced by 
TAMs, have been identified in different types of cancers 
[26, 27]. Moreover, cancer stem cells (CSC) are also 
mediated by cytokines released by TAMs and can be 
selected through overexpression of cytokines identified 
through gene arrays [28]. In addition to TAM-mediated 
cytokine release, recruitment of inflammatory cells to the 
tumor microenvironment is also influenced by hypoxic 
conditions in the tumor. For instance, hypoxic conditions 
cause hypoxia-sensitive genes to be expressed in tumor 
cells, resulting in the recruitment of inflammatory cells 
such as macrophages and granulocytes to the tumor 
microenvironment [29, 30], which will in turn contribute 
to the production of reactive oxygen species (ROS), 
leading to the activation of the nuclear factor κB (NF-κB)
pathway and subsequent secretion of TNFα and other pro-
inflammatory cytokines to promote cell proliferation [31]. 
The host immune response to a tumor greatly 
impacts the tumor microenvironment and the latter can 
in turn attenuate the immune response. These processes 
are extremely interconnected. In particular, tumor cells 
and the tumor microenvironment can contribute to the 
evasion and suppression of the host immune response. 
Inflammatory cells infiltrate tumors as part of the immune 
response to slow tumor progression. This process is known 
as immune surveillance [32]. The immune cells infiltrating 
the tumor contain cells from both the adaptive and innate 
immune responses. Adaptive immune response cells 
include tumor-infiltrating lymphocytes (TILs), dendritic 
cells, and B cells, while innate immune response cells 
include macrophages, polymorphonuclear leukocytes 
and a few natural killer cells [33]. Of these, TILs are the 
major component of immune infiltrates in tumors. These 
cells are affected greatly by antigens released in the tumor 
microenvironment, resulting in decreased lymphocyte 
proliferation, decreased signaling through T cell receptors, 
and reduced ability to mediate cytotoxicity of tumor 
targets. This collective immune suppressive effort for TILs 
allows the tumor to escape destruction by immune systems 
[34, 35]. 
Interestingly, besides the tumor itself and the tumor 
environment, one type of T cell, namely the regulatory 
T cells (Tregs), also contribute greatly to the immune 
suppressive effect. Tregs accumulate and expand in 
the tumor microenvironment and produce excessive 
interleukin 10 (IL-10) and TGFβ1. Contact-dependent 
interactions of IL-10 and TGFβ1 with T cells lead to 
decreased proliferation of immune cells and prevent the 
adaptive immune response. On the other hand, increased 
levels of TGFβ1 also promotes tumor cell proliferation, 
leading to increased tumor formation. In addition to the 
above functions, increased levels of Tregs also interfere 
with the function of anti-tumor effector cells known as 
cytotoxic T lymphocytes (CTLs), preventing their function 
of signaling the destruction of tumor cells [36].
Collectively, the above evidence suggests complex 
interactions between tumor cells, tumor environment, and 
the smart escape of tumor cells from the host immune 
responses.
CANCER ASSOCIATED FIBROBLASTS 
(CAFS)
 Researchers have long believed that tumors 
are “wounds that do not heal” [37] CAFs are activated 
fibroblasts that share similarities with fibroblasts, 
including the deposition of ECM. The tumor 
microenvironment, including epithelial differentiation, 
inflammation, and wound healing [38, 39] promotes tumor 
growth, angiogenesis, inflammation, and metastasis by 
various mechanisms [40]. Different cellular origins and 
tumor-derived factors shape the phenotype of CAFs and 
contribute to their appearance as a heterogeneous cell 
population with distinct subtypes. The activation factor 
of CAFs might vary. Several activation factors have 
been frequently reported in the stromal fibroblasts of 
solid tumors, including α-smooth muscle actin (α-SMA), 
fibroblast-specific protein, PDGF receptors-β and 
fibroblast activation protein (FAP) [41-43].
The role of CAFs in tumor progression is multi-
faceted as they can either inhibit or promote malignant 
growth [44]. In the early stages of tumor progression, 
CAFs function as repressors by facilitating the formation 
of gap junctions between activated fibroblasts and 
leading to contact inhibition on cancer cells. However, 
at a later stage, CAFs become activated by several 
tumor-secreted factors, such as TGFβ1, PDGFα/β, basic 
fibroblast growth factor (b-FGF), or interleukin 6 (IL-6) 
[44], resulting in the promotion of both tumor growth 
and progression [44]. However, what exactly may cause 
the CAFs’ transition from “tumor suppressor” to “tumor 
promoter” during tumor progress is still not completely 
clear. Recently, Liu lab reported that the activity of 
Notch1 signaling pathway negatively regulates tumor 
growth phenotype in CAFs [45]. In a skin melanoma 
mouse model, Liu’s group reported that CAF carrying 
elevated Notch1 activity significantly inhibited melanoma 
growth and invasion, while CAFs with null Notch1 
promoted melanoma invasion [45]. The role of CAFs 
in cancer progression expands a wide range, including 
ECM remodeling, secretion of soluble factors, regulation 
of motility and stemness, tumor metabolism remodeling, 
and preparation of metastatic niche. CAFs affect tumor 
cell proliferation through growth factors, hormones, and 
cytokines [44]. For instance, CAFs from hepatocellular 
carcinoma (HCC) (H-CAFs) promoted the growth of 
HCC and correlated positively with tumor size. The 
concentration of hepatocyte growth factor (HGF) secreted 
in the conditioned medium of H-CAFs was higher than 
that from normal skin fibroblasts (NSFs). Importantly, 
anti-HGF significantly reduced the proliferation-
Oncotarget52578www.impactjournals.com/oncotarget
promoting capability of H-CAFs [46]. This example 
inarguably supports the promoting role of H-CAFs related 
microenvironment in HCC tumor growth and therapy. 
TRANSCRIPTION FACTORS AND 
MICROENVIRONMENT
Researchers recently noticed that the transcription 
factor, the NF-κB plays a central role to link the 
inflammatory state and colon cancer. In addition to NF-κB 
stimulating the proliferation of tumor cells and enhancing 
their survival through the regulation of anti-apoptotic 
genes [47], an important function of NF-κB is regulating 
the expression of various cytokines and growth factors 
which contribute the tumor promoting microenvironment, 
resulting in tumor progression. Interestingly, different 
types of post-translational modifications can regulate 
NF-κB activity, including methylation, phosphorylation, 
ubiquitination, and acetylation. Recent evidence from our 
laboratory indicates that NF-κB can be phosphorylated 
at multiple sites (S316, S529 and S536) in response to 
interleukin 1β (IL-1β) treatment. These three sites either 
individually or cooperatively, regulated the secretion of 
distinct groups of NF-κB-dependent cytokines and growth 
factors, leading to an autocrine loop that in turn further 
activated NF-κB and promoter colon cancer progression 
[48]. 
Besides the posttranslational modification of NF-κB 
itself, novel activators of NF-κB, such as the transcription 
factor Y-box protein 1 (YBX1) is highly expressed 
in many cancers and is an excellent marker for cancer. 
YBX1 was recently investigated by our lab, and we found 
that overexpression of YBX1 is connected to activation 
of NF-κB. This leads to the secretion of a group of pro-
inflammatory cytokines such as TNFα and TGFβ, which 
in turn activates the expression of genes encoding other 
inflammatory cytokines, cell adhesion molecules, and cell 
survival proteins. This expression leads to the accelerated 
colon cancer progression [49]. We further found that 
YBX1 can be activated through phosphorylation on its 
S165 residue. Mutation of S165-A (alanine) on YBX1 led 
to decreased cytokine and chemokine secretion, as well 
as reduced cell growth and tumorigenic ability in colon 
cancer cells [49]. 
TUMOR MICROENVIRONMENT INDUCES 
DRUG RESISTANCE
The cytokines in the microenvironment not only 
can contribute to tumor growth, invasion, and metastasis, 
but in some situations they also drive the development of 
drug resistance. Resistance of anti-cancer drugs is a major 
cause of treatment failure in cancer. Recent studies on 
therapeutic resistance mechanisms have been conferred 
largely by alterations not in the tumor cells, but in their 
environment, indicating the importance of understanding 
the tumor cell heterogeneity [50]. For instance, in 
healthy tissue, the stroma functions as the main barrier 
against tumorigenesis. However, in the presence of 
the tumor, the stroma converts the environment to 
support cancer progression. Researchers noticed that the 
microenvironment could affect tumor vasculature, which 
serves as a barrier to optimal drug delivery [51]. A study 
showed that cytoreduction (referring to reducing the 
number of cancer cells) of the stroma through enzymatic 
destruction of hyaluronan, could reduce interstitial 
pressure and improve vessel patency and flow. This would 
lead to drug delivery improvement, as indicated by the 
increased efficacy of standard-of-care chemotherapy when 
combined with hyaluronan depletion in an animal model 
of pancreatic cancer (PC) [52]. To date, scientists have 
identified some critical molecular signaling pathways 
that are involved in the soluble factor-mediated drug 
resistance. One example involves stromal cell-derived 
factor 1 (SDF1) and its membrane-bound receptor, 
chemokine (C-X-C motif) receptor 4 (CXCR4). In chronic 
lymphocytic leukemia (CLL) cells, SDF1 produced 
by stromal cells can interact with CXCR4 and activate 
extracellular signal-regulated kinase 1/2 (ERK1/2) and 
Akt (also known as protein kinase B (PKB)) pathways, 
leading to anti-apoptotic responses and promoting tumor 
cell survival [53, 54]. Moreover, SDF1-mediated CXCR4 
activation induces resistance to chemotherapy drug 
Cytarabine, by downregulating microRNA let-7a and 
promoting transcriptional activation of Myc and BCL2-
like 1 isoform 1 (BCL-xL) in acute myeloid leukemia 
(AML) cells [55]. In human colon cancer, CXCR4 
is overexpressed in the chemoresistant tumor cells. 
Stromal cells from lymph nodes promote resistance to 
5-fluorouracil and oxaliplatin through a SDF1/CXCR4 
dependent mechanism [56].
PERSPECTIVES
Targeting cytokines or growth factors 
therapeutically
As seen in Figure 1, cancer is regulated by much 
more than just the cells of the tumor. Because of this, 
the microenvironment’s effect on tumor growth and 
survival must be considered. Instead of a single tumor 
cell, it could be more beneficial to specifically target 
the pro-tumorigenic factors supplied by innate immune 
cells during chronic inflammation, such as treatment of 
colitis-associated colon cancer (CAC). Colon cancer 
is one of the leading causes of cancer-related mortality 
in US. The limited success achieved by only targeting 
tumor cells highlights the importance of understanding 
the role of the tumor microenvironment and its precise 
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contribution to carcinogenesis. Inflammation, especially 
chronic inflammation, is a critical factor for colon tumor 
microenvironment. Clinical studies have proven that 
long-term use of nonsteroidal anti-inflammatory drugs 
by targeting cyclooxygenase-2 (COX-2) reduces the risk 
of colon cancer by 40-50% [57]. Furthermore, colitis or 
inflammatory bowel disease (IBD) is a key predisposing 
factor for colon cancer [47]. 
Though inhibition of cytokines or growth factors 
holds great therapeutic potentials, there are few federal 
Food and Drug Administration (FDA) approved examples. 
A wonderful clinical example is the application of 
Sultuximab, an anti-IL-6 in the treatment of smoldering 
multiple myeloma [58]. Additionally, Bevacizumab, an 
effective anti-vascular endothelial growth factor (VEGF) 
antibody, has been successfully used in colon cancer 
treatment [59]. The underdevelopment of anti-cytokine 
or growth factors therapeutics potentially opens up more 
possibilities for the development of new therapeutics 
along this line. Furthermore, use of a cytokine inhibitor 
and cytokine receptor inhibitor in a combinatorial therapy 
could potentially prove more effective than a single 
therapeutic. 
Targeting the host immune system therapeutically
As we described above, since immune evasion by 
cancer cells is important for the progression of tumors [60, 
61], when considering cancer therapeutics, it is important 
to think about the strategy of re-activating the immune 
system to recognize and kill tumor cells. 
For instance, Sipuleucel-T, manufactured by 
the Dendreon Corporation, is a cell-based cancer 
immunotherapy for prostate cancer. It consists of 
peripheral blood mononuclear cells (PBMCs) that 
are fused with a prostatic acid phosphatase (PAP). 
Sipuleucel-T acts to stimulate antitumor T-cell response 
in prostate tumor cells containing PAP [62]. Another 
immunotherapeutic is ipilimumab, which is a monoclonal 
antibody that works to activate the immune system by 
targeting CTLA-4, a protein receptor that downregulates 
the immune responses of CTLs. Ipilimumab turns off this 
inhibitory mechanism by CTLA -4, allowing CTLs to 
function [62].
A recent hot topic in therapeutics for the immune 
system is the programmed death ligand 1 (PD-L1)/
programmed death 1 (PD1) axis. PD1 is an immune 
inhibitory receptor expressed on several immune cells, 
Figure 1: General model of tumor and microenvironment interactions. Non cancer cells (such as CAFs, TAMs, Tregs, TILs), 
secreted factors (such as cytokines, chemokines, growth factors etc.), proteins (such as MMPs), transcription factors, and the ECM and 
EMT process are all involved in the interaction between tumor microenvironment with tumor cells. This complicated interaction can be the 
novel target for anti-cancer therapy in the future.
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particularly CTLs. The interaction of PD-L1 with PD-1 
inhibits T-cell activation and cytokine production. In 
normal tissue, the PD-L1/PD1 ligation is critically 
important in maintaining homeostasis of immune 
response to prevent autoimmunity during infection or 
inflammation. However, in the tumor microenvironment, 
their interaction could turn off the CTLs and in turn lead 
to the immune escape of tumor cells. Consequently, 
disruption of the PD-L1/PD1 axis by inhibitors will boost 
the immune response against cancer. Recently, many 
therapeutics targeting the PD-L1/PD-1 axis were used in 
Phase I, II, and III clinical trials for a variety of cancers. 
These include nivolumab, pembrolizumab, which are 
PD-1 inhibitors, and durvalumab, avelumab as well as 
atezolizumab, which are PD-L1 inhibitors. All of these 
target the PD-L1/PD1 axis [63]. The response rate of 
patients to the therapeutics were highly variable, ranging 
from 80% with pembrolizumab in advanced Merkel cell 
carcinoma (MCC), a rare type of skin cancer, to 12% 
with durvalumab in recurrent/metastatic squamous cell 
carcinoma of head and neck (SCCHN). While some 
therapeutics were not very effective in clinical trials, 
almost all tested therapeutic approaches were a single 
therapeutic as opposed to combinatorial therapies. To 
date, few combinatorial therapies involving PD-L1/PD1 
axis have been tried. Theoretically, combinations of PD-1 
or PD-L1 inhibitors with other therapeutic approaches 
could potentially provide a more effective therapeutic 
strategy for patients. It won’t be a huge surprise to see 
more exciting work coming out along this line of research 
in the near future.
Challenges ahead
Despite the success in targeting non-tumor cell 
compartments in the past, significant challenges still lie 
ahead for implementing stromal targeting strategies in 
clinical practice. These range from difficulties in assessing 
the composition of the stroma in human tumors to correctly 
modeling pre-clinically the vast heterogeneity observed 
in human tumors and correlating this heterogeneity with 
outcome, drug response, and drug resistance [50]. For 
example, PC is an aggressive malignant disease with 
a 5-year survival rate of less than 5%. PC is one of the 
few cancers for which survival has not been improved 
substantially over nearly 40 years mainly due to limited 
success of target therapies. One reason for failure of 
systemic therapies is related to the abundant tumor stromal 
contents in the tumor microenvironment. The tumor 
microenvironment is constantly changing in composition. 
PC stroma is very heterogeneous and comprised of 
cellular components, such as fibroblasts, myofibroblasts, 
pancreatic stellate cells, immune cells, blood vessels, 
ECM, and soluble proteins such as cytokines and growth 
factors. PC stroma supports tumor growth and promotes 
metastasis and simultaneously serves as a physical barrier 
to drug delivery [64]. Understanding and altering stromal 
composition or function will definitely benefit the patients. 
An additional consideration is the potential off-
target effect. In the case of cytokines such as TGFβ or 
TNFα, the ubiquitousness of the cytokines may result in 
unforeseen off-target effects when targeting them with 
therapeutics [65]. For instance in Feyen et al.’s work 
TNFα inhibitors were not selective simply for TNFα, but 
could target many other proteins leading to unforeseen 
complications for patients. Since many cytokines are 
involved in several different signaling pathways such 
as the NF-κB pathway and MAPK pathways, targeting 
the cytokine itself can cause issues as it will change 
signaling in pathways not intended to be targeted. To be 
truly selective in our targeting of cancer cells, we must 
develop and use therapeutics that are more specific to 
what is involved between a tumor microenvironment 
and the tumor itself, but not normal cells. Additionally, 
changes in the tumor microenvironment can contribute 
to development of resistance, preventing rejection of the 
tumor by the immune system. Changes in the balance of 
cytokines such as VEGF, TGFβ, IL-4, IL-12 and others 
can actively suppress dendritic cell (DC) maturation which 
dampens the antigen presenting function of DCs, which 
then contributes to immune tolerance [66]. These are all 
the factors that we must consider in terms of developing 
novel anti-microenvironment therapies. 
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